

Hemovigilance Module Adverse Reaction Transfusion Associated Graft vs. Host Disease

*Required for savin									
*Facility ID#:	NHSN Adverse Reaction #:								
Patient Informatio	n								
*Patient ID:	*Date of Birth://								
*Sex:MF									
	Secondary ID: Medicare #:								
Last Name:									
Ethnicity (Specify):	Hispanic or Latino								
Race (Select all that apply):	American Indian or Asian Black or African Middle Eastern or North Alaska Native American African Native Hawaiian or White Unknown Declined to respond Pacific Islander Image: Comparison of the co								
Preferred Language (Specify from the list provided): Interpreter Needed: Yes Unknow Unknow Unknow n								
*Blood Group: A- A+ B- + AB- AB+ O- O+ Blood type not done Transitional ABO / Rh + Transitional ABO / Rh - Transitional ABO / Rh - Rh Group A/Transitional Rh Group B/Transitional Rh Group O/Transitional Group AB/Transitional Rh									
Patient Medical Hi									
	dmitting diagnosis. (Use ICD-10 Diagnostic codes/descriptions)								
Code:									
Code:									
Code:									
	nderlying indication for transfusion. (Use ICD-10 Diagnostic codes/descriptions)								
Code:									
Code:									
Code:									
List the patient's co	omorbid conditions at the time of the transfusion related to the adverse UNKNOWN -10 Diagnostic codes/descriptions) NONE								
Code:	Description:								
Code:									
Code:									

Assurance of Confidentiality: The voluntarily provided information obtained in this surveillance system that would permit identification of any individual or institution is collected with a guarantee that it will be held in strict confidence, will be used only for the purposes stated, and will not otherwise be disclosed or released without the consent of the individual, or the institution in accordance with Sections 304, 306 and 308(d) of the Public Health Service Act (42 USC 242b, 242k, and 242m(d)). CDC 57.316 Rev. 3, v9.2

Public reporting burden of this collection of information is estimated to average 20 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering, and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC, Reports Clearance Officer, 1600 Clifton Rd., MS H21-8, Atlanta, GA 30333, ATTN: PRA (0920-0666).



Form Approved OMB No. 0920-0666 Exp. Date: 12/31/2027 www.cdc.gov/nhsn



	nedical procedure including past procedures and procedures to be UNKNOWN
codes/descriptions)	nedical procedure including past procedures and procedures to be UNKNOWN nt hospital or outpatient stay. (Use ICD-10 Procedure NONE
Code:	Description:
Code:	
Code:	Description:
Additional Information	
Transfusion History	
Date of Transfusion:	previous transfusion? YES NO UNKNOWN WB RBC Platelet Plasma Cryoprecipitate Granulocyte // UNKNOWN e reaction transfusion-related? YES NO
Type of transfusion adver	n about the transfusion adverse reaction. rse reaction: Allergic AHTR DHTR DSTR FNHTR PTP TACO TAD TA-GVHD TRALI UNKNOWN fy
Reaction Details	
*Date reaction occurred:	// *Time reaction occurred: : Time unknown
*Facility location where pati	ent was transfused:
Is this reaction associated with	h an incident? Yes No If Yes, Incident #:
Investigation Results	
* Transfusion associated	l graft vs. host disease (TA-GVHD)
*Case Definition	
	radiated blood product(s) in the two months preceding the reaction?
Did patient receive non-irr	radiated blood product(s) in the two months preceding the reaction? Yes No within 2 days to 6 weeks after cessation of transfusion:
Did patient receive non-irr	
Did patient receive non-irr Check all that occurred v Clinical syndrome Clinical syndrome	
Did patient receive non-im Check all that occurred v Clinical syndrome Clinical syndrome Liver dysfunc Characteristic	within 2 days to 6 weeks after cessation of transfusion:
Did patient receive non-im Check all that occurred w Clinical syndrome Clinical syndrome Liver dysfunc Characteristic may, in severe ca Check all that apply: Characteristic histol	within 2 days to 6 weeks after cessation of transfusion: e characteristics: Diarrhea Fever Hepatomegaly Pancytopenia tion (i.e., elevated ALT, AST, Alkaline phosphatase, and bilirubin) Marrow aplasia c rash: erythematous, maculopapular eruption centrally that spreads to extremities and ases, progress to generalized erythroderma and hemorrhagic bullous formation. logical appearance of skin or liver biopsy.
Did patient receive non-irr Check all that occurred w Clinical syndrome Clinical syndrome Liver dysfunc Characteristic may, in severe ca Check all that apply: Characteristic histol Biopsy negative or n	within 2 days to 6 weeks after cessation of transfusion: e characteristics: Diarrhea Fever Hepatomegaly Pancytopenia tion (i.e., elevated ALT, AST, Alkaline phosphatase, and bilirubin) Marrow aplasia c rash: erythematous, maculopapular eruption centrally that spreads to extremities and ases, progress to generalized erythroderma and hemorrhagic bullous formation. logical appearance of skin or liver biopsy. not done.
Did patient receive non-im Check all that occurred v Clinical syndrome Clinical syndrome Liver dysfunc Characteristic may, in severe ca Check all that apply: Characteristic histol	within 2 days to 6 weeks after cessation of transfusion: e characteristics: Diarrhea Fever Hepatomegaly Pancytopenia tion (i.e., elevated ALT, AST, Alkaline phosphatase, and bilirubin) Marrow aplasia c rash: erythematous, maculopapular eruption centrally that spreads to extremities and ases, progress to generalized erythroderma and hemorrhagic bullous formation. logical appearance of skin or liver biopsy. not done. : (check all that apply)
Did patient receive non-irr Check all that occurred w Clinical syndrome Clinical syndrome Liver dysfunc Characteristic may, in severe ca Check all that apply: Characteristic histol Biopsy negative or w Other signs and symptoms Generalized:	within 2 days to 6 weeks after cessation of transfusion: e characteristics: Diarrhea Fever Hepatomegaly Pancytopenia tion (i.e., elevated ALT, AST, Alkaline phosphatase, and bilirubin) Marrow aplasia c rash: erythematous, maculopapular eruption centrally that spreads to extremities and ases, progress to generalized erythroderma and hemorrhagic bullous formation. logical appearance of skin or liver biopsy. not done. : (check all that apply) Chills/rigors
Did patient receive non-irr Check all that occurred w Clinical syndrome Clinical syndrome Liver dysfunc Characteristic may, in severe ca Check all that apply: Characteristic histol Biopsy negative or m Other signs and symptoms	within 2 days to 6 weeks after cessation of transfusion: e characteristics: Diarrhea Fever Hepatomegaly Pancytopenia tion (i.e., elevated ALT, AST, Alkaline phosphatase, and bilirubin) Marrow aplasia c rash: erythematous, maculopapular eruption centrally that spreads to extremities and ases, progress to generalized erythroderma and hemorrhagic bullous formation. logical appearance of skin or liver biopsy. not done. : (check all that apply)



-	Hemolysis/Hemorrhage:	e: Disseminated intravascular coagulation Hemoglobinemia						inemia			
Deini			Positive antibody screen								
-	Pain:		Abdominal pain Back pain Flank pa					L_	Infusion site pain		
-	Renal:	╞┝═	Hematuria	╞	Hemoglobinuria		Oligur				
	Respiratory:		Bronchospasm		Cough		Shortr	ness	of breath		
	Other: (specify)								<u></u>		
	*Severity										
	Did the patient receive or	. exb	erience any of the fo	llo	wing?						
	No treatment requ	iired			Symptomatic treatmer	nt o	nly				
	Hospitalization, inlcuding prolonged hospitalization										
	Disability and/or ir	ncap	acitation		Congenital anomaly o	r bi	rth def	fect(s	s) of the fetus		
	Other medically in	npor	ant conditions		Death I	Jnk	nown	or no	ot stated		
		<u> </u>									
	*Imputability						-				
	Which best describes the		•	e tra	ansfusion and the react	ion	?				
	No other alternative		•								
					cell transplantation).						
			, , ,		solid organ transplantat						
	Evidence is clearly	in fa	vor of a cause other	tha	in the transfusion, but t	ran	sfusio	n cai	nnot be excluded.		
	There is conclusive	evid	ence beyond reasor	۱ab	le doubt of a cause oth	ert	han th	ne tra	Insfusion		
	The relationship be	twee	n the adverse reacti	on	and the transfusion is u	Ink	10wn (or no	it stated.		
	Did the transfusion occur	at yo	our facility?	YE	S NO						
	WBC chimerism:		3C chimerism prese	nt	WBC chimer	ism	not p	rese	nt or not done		
Мс	dule-generated Desig	jnat	ions								
NOTE: Designations for case definition, severity, and imputability will be automatically assigned in the NHSN application based on responses in the corresponding investigation results section above.											
*Do you agree with the <u>case definition</u> designation?											
	^Please indicate your de	signa	ation								
	*Do you agree with the	seve	erity designation?				YES		NO		
	^Please indicate your de						-				
	*Do you agree with the	imn	utability designatio	m?			YES		NO		
	^Please indicate your de	-									
Pa	tient Treatment										
[Did the patient receive trea	tmer	nt for the transfusion	rea	action?	3	1	NO	UNKNOWN		
	If yes, select treatment(s):										
	Medication (Select the type of medication)										
	Antipyretics Antihistamines Inotropes/Vasopressors Bronchodilator Diuretics										
	Immunoglobulin Intravenous steroids Corticosteroids Antibiotics								Antibiotics		
	Antithymocyte globulin Cyclosporin Other										
	Page 4 of 6										
			Paye 4 0	υ							

NATIONAL HEAL SAFETY NETV	SN THCARE VORK						OMB No. Exp. Date:	n Approved 0920-0666 12/31/2027 lc.gov/nhsn				
Volume resuscitation (Intravenous colloids or crystalloids)												
Respiratory support <i>(Select the type of support)</i> Mechanical ventilation Noninvasive ventilation Oxygen												
Renal replacement therapy (Select the type of therapy) Hemodialysis Peritoneal Continuous Veno-Venous Hemofiltration												
Phlebotomy												
	Other Specify:											
Outcome				-	1	. 「						
	*Outcome: Death Major or long-term sequelae Minor or no sequelae Not determined											
Date of Death://												
	Definite Probabl	•	_		Ruled Ou	t 🗆 N	Not determine	ed				
Cause	of death:					•						
Was an	Was an autopsy performed?											
Component	Details											
-	cular unit implicated	d in (i.e., respo	onsibl	e for) the a	dverse	Yes	No	N/A				
		Amount		number	*1 1 1 2 1			Implicat				
Start and End Date/Time	Start and End *Component code transfused at Infect			ired for on and I)	*Unit expiration Date/Time	*Blood of unit	group	Implicat ed Unit?				
^IMPLICATED	UNIT				•	·						
<u> </u>	ISBT-128											
:	Codabar	Entire unit				A-	A+ B-					
1 1		Partial unit mL				B+ AE] 3- AB+	Y				
//							0+ N/A					
· · · ·	ISBT-128				·							
· · · · · · · · · · · · · · · · · · ·	Codabar	Entire unit	<u> </u>			A-	А+ В-					
· ·		Partial unit			/			N				
//	·	mL				B+ AE						
: OO+N/A												
Custom Field	15			Label								
		!	-				''					
Comments												

